Library Subscription: Guest
Begell Digital Portal Begell Digital Library eBooks Journals References & Proceedings Research Collections
Critical Reviews™ in Immunology
IF: 1.404 5-Year IF: 3.347 SJR: 0.706 SNIP: 0.55 CiteScore™: 2.19

ISSN Print: 1040-8401
ISSN Online: 2162-6472

Volumes:
Volume 40, 2020 Volume 39, 2019 Volume 38, 2018 Volume 37, 2017 Volume 36, 2016 Volume 35, 2015 Volume 34, 2014 Volume 33, 2013 Volume 32, 2012 Volume 31, 2011 Volume 30, 2010 Volume 29, 2009 Volume 28, 2008 Volume 27, 2007 Volume 26, 2006 Volume 25, 2005 Volume 24, 2004 Volume 23, 2003 Volume 22, 2002 Volume 21, 2001 Volume 20, 2000 Volume 19, 1999 Volume 18, 1998 Volume 17, 1997 Volume 16, 1996 Volume 15, 1995 Volume 14, 1994

Critical Reviews™ in Immunology

DOI: 10.1615/CritRevImmunol.v27.i5.50
pages 463-483

Immunogenicity of Dendritic-Tumor Fusion Hybrids and Their Utility in Cancer Immunotherapy

Suyu Shu
Center for Surgery Research, NE6-307, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
Rongxiu Zheng
Center for Surgery Research, NE6-307, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
Walter T. Lee
Center for Surgery Research, NE6-307, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA
Peter A. Cohen
Center for Surgery Research, NE6-307, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195, USA

ABSTRACT

Cancer immunotherapy using fusion hybrid cells generated from dendritic cells (DCs) and tumor cells may be more effective than other DC−based vaccines. DC−tumor fusion potentially confers not only the DCs' antigen-presenting functionality but also a continuing source of endogenous tumor antigens for major-histocompatibility-complex-restricted T−cell sensitization. In animal models, many investigators demonstrated that vaccination with fusion hybrids was protective against tumor challenge and therapeutic, resulting in the regression of established tumors. In clinical trials for patients with a variety of metastatic diseases, fusion hybrid vaccines were well tolerated, but the overall objective response rate was only 10.9%. Careful scrutiny of a large number of publications revealed that, in most cases, no definitive evidence of heterokaryonic fusion cell formation was found. Further corroboration of this conclusion comes from reports that fusion hybrids generated from autologous (syngeneic) and allogeneic DCs displayed equivalent immunological function and therapeutic effects in vitro and in vivo. This puzzling finding suggests that effective fusion immunotherapy depends on tumor antigen scavenging and presentation by antigen-presenting cells (APCs) of host origin and is in violation of the basic tenet of the principle of DC function. We believe that conclusions drawn from reported clinical trials have not properly evaluated the efficacy of the DC−tumor hybrid vaccine, and therefore, they neither confirm nor disclaim the potential benefits that may be derived from this form of immunotherapy.


Articles with similar content:

Improving Immunotherapy by Conditionally Enhancing MHC Class I Presentation of Tumor Antigen-Derived Peptide Epitopes
Critical Reviews™ in Immunology, Vol.27, 2007, issue 5
Ronald M. Bukowski, Mayumi Kawabe, Peter A. Cohen, James H. Finke, Amy K. Wesa, Walter J. Storkus, Christopher Herrem
In Vitro Immunization and Expansion of Antigen-Specific Cytotoxic T Lymphocytes for Adoptive Immunotherapy Using Peptide-Pulsed Dendritic Cells
Critical Reviews™ in Immunology, Vol.18, 1998, issue 1-2
Alessandro Sette, Van Tsai, Esteban Celis, Ichiro Kawashima, Elissa Keogh, Kieran Daly
Dendritic Cells, Interleukin 12, and CD4+ Lymphocytes in the Initiation of Class l-restricted Reactivity to a Tumor/Self Peptide
Critical Reviews™ in Immunology, Vol.18, 1998, issue 1-2
Emira Ayroldi, Maria Laura Belladonna, Maria Cristina Fioretti, Daniela Surace, Silvia Silla, Paolo Puccetti, Ursula Grohmann, Roberta Bianchi
Dendritic Cell Cross Talk with Innate and Innate-like Effector Cells in Antitumor Immunity: Implications for DC Vaccination
Critical Reviews™ in Immunology, Vol.34, 2014, issue 6
I. Jolanda M. de Vries, Jasper J. P. van Beek, Annette E. Skold, Stanleyson V. Hato, Florian Wimmers
Tumor Antigen Presentation by Dendritic Cells
Critical Reviews™ in Immunology, Vol.30, 2010, issue 4
Nina Dickgreber, Ian F. Hermans, Troels R. Petersen